Revelation Biosciences (REVB) Research & Development (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Research & Development of $964190.0 for Q4 2025, up 869.79% year-over-year from $99423.0 in Q4 2024, and up 3772.72% quarter-over-quarter from $24897.0 in Q3 2025.
Revelation Biosciences (REVB) Research & Development (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Research & Development for 5 consecutive years, with $964190.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development rose 869.79% year-over-year to $964190.0; the TTM figure through Dec 2025 stood at $1.0 million (up 219.83% YoY), while the FY2025 annual figure was $4.1 million, up 2257.65% from the prior year.
- Research & Development rose to $964190.0 in Q4 2025 per REVB's latest filing, from $24897.0 in the prior quarter.
- Across five years, Research & Development topped out at $3.7 million in Q1 2022 and bottomed at $20570.0 in Q2 2025.
- Historically, Research & Development has averaged $889719.6 across 5 years, with a median of $717275.5 in 2023.
- Annual changes were most pronounced in 2024 — Research & Development sank 98.64% — and 2025, when it soared 869.79%.
- Revelation Biosciences' Research & Development stood at $2.7 million in 2021, then sank by 87.25% to $339971.0 in 2022, then jumped by 211.79% to $1.1 million in 2023, then tumbled by 90.62% to $99423.0 in 2024, then jumped by 869.79% to $964190.0 in 2025.
- Business Quant data shows REVB's Research & Development at $964190.0 in Q4 2025, $24897.0 in Q3 2025, and $20570.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Revelation Biosciences | 4.10 Mn | -7.40 Mn | - | 1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.92 Mn |
| Dec 31, 2025 | 964,190.00 |
| Sep 30, 2025 | 24,897.00 |
| Jun 30, 2025 | 20,570.00 |
| Mar 31, 2025 | 23,613.00 |
| Dec 31, 2024 | 99,423.00 |
| Sep 30, 2024 | 22,447.00 |
| Jun 30, 2024 | 112,180.00 |
| Mar 31, 2024 | 89,015.00 |
| Dec 31, 2023 | 1.06 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 909,278.00 |
| Mar 31, 2023 | 525,273.00 |
| Dec 31, 2022 | 339,971.00 |
| Sep 30, 2022 | 381,566.00 |
| Jun 30, 2022 | 975,583.00 |
| Mar 31, 2022 | 3.68 Mn |
| Dec 31, 2021 | 2.67 Mn |
| Sep 30, 2021 | 1.53 Mn |
| Jun 30, 2021 | 1.16 Mn |